DOCSLIB.ORG

IL36RN Mutations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The University of Manchester Research IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis DOI: 10.1016/j.jid.2019.08.444 Document Version Accepted author manuscript Link to publication record in Manchester Research Explorer Citation for published version (APA): Catapano, M., Vergnano, M., Romano, M., Mahil, S. K., Choon, S., Burden, A. D., Young, H. S., Carr, I. M., Lachmann, H. J., Lombardi, G., Smith, C. H., Ciccarelli, F. D., Barker, J. N., & Capon, F. (2019). IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2019.08.444 Published in: Journal of Investigative Dermatology Citing this paper Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version. General rights Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Takedown policy If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact [email protected] providing relevant details, so we can investigate your claim. Download date:03. Oct. 2021 Journal of Investigative Dermatology Interleukin-36 promotes systemic Type-I IFN responses in severe forms of psoriasis Journal: Journal of Investigative Dermatology Manuscript ID JID-2019-0205.R1 Article Type:ForOriginal Review Article Only Date Submitted by the 14-Jun-2019 Author: Complete List of Authors: Catapano, Marika; King's College London, Division of Genetics and Molecular Medicine Vergnano, Marta; King's College London, Division of Genetics and Molecular Medicine Romano, Marco; King's College London, Department of Immunobiology, School of Immunology & Microbial Sciences Mahil, Satveer; King’s College London, Department of Medical and Molecular Genetics Choon, Siew-Eng; Hospital Sultanah Aminah, Department of Dermatology Burden, David; University of Glasgow, Department of Dermatology Young, Helen; The University of Manchester, Dermatology Research Centre Carr, Ian; University of Leeds, School of Medicine Lachmann, Helen; University College London, National Amyloidosis Centre and Centre for Acute Phase Proteins, Division of Medicine Lombardi, Giovanna; King's College London, MRC Centre for Transplantation Smith, Catherine; Kings College London, St John's Institute of Dermatology Ciccarelli, Francesca; Francis Crick Institute, Cancer Systems Biology Laboratory Barker, Jonathan; St John's Institute of Dermatology, St Thomas' Hospital, Division of Genetics and Moilecular Medicine Capon, Francesca; King's College London, Division of Genetics and Molecular Medicine Autoinflammatory Diseases, Cytokines, Inflammatory Skin Diseases, Keywords: Neutrophils, Psoriasis Page 1 of 62 Journal of Investigative Dermatology Head of School Department of 1 King’s College London Faculty of Life Sciences Professor Mathias Gautel Medical & 2 Molecular Genetics 3 & Medicine Head of Department Floor 8 Tower Wing 4 Professor Tim J P Hubbard Guy’s Hospital 5 School of Basic and London SE1 9RT 6 Medical Biosciences 7 8 http://www.kcl.ac.uk/gm 9 Please reply to: Francesca Capon 10 mReader in Inflammation Genetics 11 e-mail: [email protected] 12 13 14 15 16 17 14th June 2019 18 19 20 21 Prof Mark C Udey, For Review Only 22 Editor, Journal of Investigative Dermatology 23 24 25 Dear Prof Udey, 26 Re: MS# JID-2019-0205 27 28 We are submitting revised version of the above manuscript entitled “Interleukin-36 promotes 29 30 systemic Type-I IFN responses in severe psoriasis “. 31 32 To address the reviewers’ comments, we have undertaken the analysis of additional datasets, 33 provided more information on our patient resources and included further experimental data on IL- 34 36R expression. We believe that the manuscript, which has also been edited for clarity, is much 35 36 improved and will now meet the criteria for publication on the Journal of Investigative Dermatology. 37 38 39 I look forward to hearing from you and remain 40 41 Yours sincerely 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 www.kcl.ac.uk Journal of Investigative Dermatology Page 2 of 62 1 2 3 RESPONSE TO REVIEWERS 4 5 Reviewer 1 6 The data is reliable… however, there are too many miss spelling in the text. 7 8 We have carefully proofread the text and eliminated typos as well as instances of inconsistent spelling 9 One concern is as if the author checked IL-36RN mutation or IL-1RN mutation in GPP patients or not. 10 Based on the diagnosis of GPP, we have screened all patients for IL36RN mutations. This has now been 11 st 12 clarified in the Methods (p.11, 1 paragraph). 13 Add the comment that treatment with IL-17 antibody or IL-17R inhibitor will decrease skin 14 15 inflammation and production of IL-36 from keratinocytes, leading to the down regulation of Type-I IFN. 16 The comment has been added to the Discussion (p.10, 3rd paragraph). 17 18 Reviewer 2 19 1) It is questionable if any of the findings described is specific for IL-36 as compared to other pro- 20 21 inflammatory cytokines andFor in particular Review members of the Only IL-1 family. Importantly Swindell et al (Front 22 Immunol. 2018 Jan 29; 9:80) have demonstrated that IL1 and IL-36 signalling is essentially the same. 23 It is likely that all effects shown here would be equally inducible by other IL-1 family members some of 24 which are also upregulated in psoriatic inflammation. 25 We have revised the Discussion (p.8, 2nd paragraph), to quote the important work of Swindell et al and 26 27 acknowledge the similarities between IL-1 and IL-36 signalling. At the same time, we note that Swindell 28 did not identify any of our interferon signature genes among the transcripts induced by IL-1. In keeping 29 with this observation, we find that no IFN signature genes are up-regulated in the whole-blood of 30 patients with CAPS, a condition caused by excessive IL-1 signalling. This pattern was observed in two 31 independent datasets, the second of which was analysed as part of the revision process. The result of 32 33 this new analysis are reported in Supplementary Figure S1. 34 2) A significant body of literature highlights the role of LL-37 in psoriatic inflammation being an 35 36 important contributor to type I IFN responses also in pustular phenotype development. LL-37 is neither 37 mentioned nor included in experimental setups in this paper and should be considered to gain a more 38 balanced information on which factors contribute to clinically relevant IFN expression. Conrad et 39 al (Nat Commun. 2018 Jan 2;9(1):25) and other publications by Gilliet group. 40 The reviewer makes a very interesting point, which we have initially addressed by querying the 41 42 expression of CAMP (the gene encoding LL-37) in our transcriptomic datasets. This revealed that CAMP 43 is up-regulated in the skin of psoriatic patients (fold change >2.0, FDR <0.05), but not in their blood. 44 In keeping with the latter observation, real-time PCR showed that IL-36 treatment does not increase 45 CAMP expression in PBMCs. 46 47 LL37 48 PBMCs were stimulated with IL-36 49 3 50 for the indicated time points. Data 51 2 represent the mean (+/- SEM) of 52 triplicate stimulations 53 1 54 0 55 0h 3h 6h 8h 24h 56 57 Finally, we observed that CAMP whole-blood expression does not correlate with the up-regulation of 58 Type-I IFN genes in either GPP or PsV samples (r<0.1 in both datasets). This suggests that LL-37 is 59 unlikely to be driving the Type-I IFN responses we observed at the systemic level. 60 1 Page 3 of 62 Journal of Investigative Dermatology 1 2 3 We have now edited the Discussion (p.9, final paragraph) to mention these negative findings and 4 quote the work of the Gilliet group, which provides the underlying context. 5 6 3) The clinical relevance of an increase IFN signature (which clearly overlaps with IFNg signature – the 7 latter is known to be highly expressed in psoriasis) remains to be demonstrated. To further explore the 8 9 significance of the induced IFN response a comparison to a disease recognised for its type I IFN pathway 10 activation such as systemic lupus should be included. Some comparison with other diseases is based 11 only on literature data. Figure 1F as it stands gives too little information to demonstrated convincing 12 evidence. Has the same cell population been analysed, was treatment given to the patients, are patient 13 groups regarding to basic demographics comparable etc. 14 15 First of all, we have edited the Methods (RNA-seq data analysis, p.11) to clarify that we did not base 16 the comparisons with other diseases on gene lists published in the literature. On the contrary, we 17 retrieved raw sequence files for every dataset and processed them with the same computational 18 pipeline that was used for the QC and differential expression analysis of our own data. Thus, the up- 19 regulated genes reported in Figures 1f and S1 were identified through a robust, standardised process. 20 21 To fully document these analyses,For we Review have also added a Onlysupplementary Table S4, which summarises 22 the key features of the publicly available datasets and shows that they were all generated in whole- 23 blood samples obtained from European individuals.
Recommended publications
  • A Genetic Variant Protective Against Severe COVID-19 Is Inherited from Neandertals

    A Genetic Variant Protective Against Severe COVID-19 Is Inherited from Neandertals

    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.05.327197; this version posted October 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. A genetic variant protective against severe COVID-19 is inherited from Neandertals Authors Hugo Zeberg1,2* and Svante Pääbo1,3* Affiliations 1 Max Planck Institute for Evolutionary Anthropology, Deutscher Platz 6, D-04103 Leipzig, Germany. 2 Department of Neuroscience, Karolinska Institutet, SE-17177 Stockholm, Sweden. 3 Okinawa Institute of Science and Technology, Onna-son, Okinawa 904-0495, Japan. *Corresponding authors: [email protected], [email protected] Abstract It was recently shown that the major genetic risk factor associated with becoming severely ill with COVID-19 when infected by SARS-CoV-2 is inherited from Neandertals. Thanks to new genetic association studies additional risk factors are now being discovered. Using data from a recent genome- wide associations from the Genetics of Mortality in Critical Care (GenOMICC) consortium, we show that a haplotype at a region associated with requiring intensive care is inherited from Neandertals. It encodes proteins that activate enzymes that are important during infections with RNA viruses. As compared to the previously described Neandertal risk haplotype, this Neandertal haplotype is protective against severe COVID-19, is of more moderate effect, and is found at substantial frequencies in all regions of the world outside Africa. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.05.327197; this version posted October 9, 2020.
  • Secretion and LPS-Induced Endotoxin Shock Α Lipopolysaccharide

    Secretion and LPS-Induced Endotoxin Shock Α Lipopolysaccharide

    IFIT2 Is an Effector Protein of Type I IFN− Mediated Amplification of Lipopolysaccharide (LPS)-Induced TNF- α Secretion and LPS-Induced Endotoxin Shock This information is current as of September 27, 2021. Alexandra Siegfried, Susanne Berchtold, Birgit Manncke, Eva Deuschle, Julia Reber, Thomas Ott, Michaela Weber, Ulrich Kalinke, Markus J. Hofer, Bastian Hatesuer, Klaus Schughart, Valérie Gailus-Durner, Helmut Fuchs, Martin Hrabe de Angelis, Friedemann Weber, Mathias W. Hornef, Ingo B. Autenrieth and Erwin Bohn Downloaded from J Immunol published online 6 September 2013 http://www.jimmunol.org/content/early/2013/09/06/jimmun ol.1203305 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/09/06/jimmunol.120330 Material 5.DC1 Why The JI? Submit online. by guest on September 27, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published September 6, 2013, doi:10.4049/jimmunol.1203305 The Journal of Immunology IFIT2 Is an Effector Protein of Type I IFN–Mediated Amplification of Lipopolysaccharide (LPS)-Induced TNF-a Secretion and LPS-Induced Endotoxin Shock Alexandra Siegfried,*,1 Susanne Berchtold,*,1 Birgit Manncke,* Eva Deuschle,* Julia Reber,* Thomas Ott,† Michaela Weber,‡ Ulrich Kalinke,x Markus J.
  • Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
  • The Role of Interleukin-36 in Inflammatory Skin Diseases

    The Role of Interleukin-36 in Inflammatory Skin Diseases

    UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II DOTTORATO DI RICERCA IN MEDICINA CLINICA E SPERIMENTALE CURRICULUM IN SCIENZE IMMUNOLOGICHE E DERMATOLOGICHE XXIX Ciclo Coordinatore: Prof. Gianni Marone TESI DI DOTTORATO TITOLO The role of interleukin-36 in inflammatory skin diseases TUTOR/RELATORE CANDIDATA Chiar.mo Dott.ssa Giuseppina Caiazzo Prof. Fabio Ayala INDEX Summary .…………………………………………………………. page 2 I CHAPTER IL-36 cytokines……………………………………………………... page 3 IL-36 and their immune function………………………………….. page 5 II CHAPTER IL-36 and diseases…………………………………………………… page 7 IL-36 and skin diseases……………………………………………… page 7 Pathogenesis of psoriasis …………………………………………… page 9 Pathogenesis of allergic contact dermatitis………………………… page 12 Pathogenesis of polymorphic light eruption..………………………. page14 III CHAPTER Experimental Design………………………………………………..... page 17 Materials and methods........................................................................ page 17 Results……………………………………………………………….... page 24 VI CHAPTER Discussion……………………………………………………………… page 31 References 1 Summary Interleukin (IL)-36 cytokines are new members of the IL-1 family, that include pro- inflammatory factors, IL-36α, IL-36β and IL-36γ, and a natural receptor antagonist IL-36Ra. IL-36 cytokines are expressed in a specific manner by monocytes/macrophages, dendritic cells (DCs), T cells subsets, keratinocytes, Langerhans cells, and mucosal epithelium. Since IL-36 cytokines are predominantly expressed in keratinocytes it is not surprising that specifically skin disorders have been
  • 1A Multiple Sclerosis Treatment

    1A Multiple Sclerosis Treatment

    The Pharmacogenomics Journal (2012) 12, 134–146 & 2012 Macmillan Publishers Limited. All rights reserved 1470-269X/12 www.nature.com/tpj ORIGINAL ARTICLE Network analysis of transcriptional regulation in response to intramuscular interferon-b-1a multiple sclerosis treatment M Hecker1,2, RH Goertsches2,3, Interferon-b (IFN-b) is one of the major drugs for multiple sclerosis (MS) 3 2 treatment. The purpose of this study was to characterize the transcriptional C Fatum , D Koczan , effects induced by intramuscular IFN-b-1a therapy in patients with relapsing– 2 1 H-J Thiesen , R Guthke remitting form of MS. By using Affymetrix DNA microarrays, we obtained and UK Zettl3 genome-wide expression profiles of peripheral blood mononuclear cells of 24 MS patients within the first 4 weeks of IFN-b administration. We identified 1Leibniz Institute for Natural Product Research 121 genes that were significantly up- or downregulated compared with and Infection Biology—Hans-Knoell-Institute, baseline, with stronger changed expression at 1 week after start of therapy. Jena, Germany; 2University of Rostock, Institute of Immunology, Rostock, Germany and Eleven transcription factor-binding sites (TFBS) are overrepresented in the 3University of Rostock, Department of Neurology, regulatory regions of these genes, including those of IFN regulatory factors Rostock, Germany and NF-kB. We then applied TFBS-integrating least angle regression, a novel integrative algorithm for deriving gene regulatory networks from gene Correspondence: M Hecker, Leibniz Institute for Natural Product expression data and TFBS information, to reconstruct the underlying network Research and Infection Biology—Hans-Knoell- of molecular interactions. An NF-kB-centered sub-network of genes was Institute, Beutenbergstr.
  • Entinostat Augments NK Cell Functions Via Epigenetic Upregulation of IFIT1-STING-STAT4 Pathway

    Entinostat Augments NK Cell Functions Via Epigenetic Upregulation of IFIT1-STING-STAT4 Pathway

    www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 20), pp: 1799-1815 Research Paper Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway John M. Idso1, Shunhua Lao1, Nathan J. Schloemer1,2, Jeffrey Knipstein2, Robert Burns3, Monica S. Thakar1,2,* and Subramaniam Malarkannan1,2,4,5,* 1Laboratory of Molecular Immunology and Immunotherapy, Blood Research Institute, Versiti, Milwaukee, WI, USA 2Division of Pediatric Hematology-Oncology-BMT, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA 3Bioinformatics Core, Blood Research Institute, Versiti, Milwaukee, WI, USA 4Divson of Hematology-Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA 5Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA *Co-senior authors Correspondence to: Monica S. Thakar, email: [email protected] Subramaniam Malarkannan, email: [email protected] Keywords: NK cells; histone deacetylase inhibitor; Ewing sarcoma; rhabdomyosarcoma; immunotherapy Received: September 10, 2019 Accepted: March 03, 2020 Published: May 19, 2020 Copyright: Idso et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Histone deacetylase inhibitors (HDACi) are an emerging cancer therapy; however, their effect on natural killer (NK) cell-mediated anti-tumor responses remain unknown. Here, we evaluated the impact of a benzamide HDACi, entinostat, on human primary NK cells as well as tumor cell lines. Entinostat significantly upregulated the expression of NKG2D, an essential NK cell activating receptor. Independently, entinostat augmented the expression of ULBP1, HLA, and MICA/B on both rhabdomyosarcoma and Ewing sarcoma cell lines.
  • Microarray Analysis of Novel Genes Involved in HSV- 2 Infection

    Microarray Analysis of Novel Genes Involved in HSV- 2 Infection

    Microarray analysis of novel genes involved in HSV- 2 infection Hao Zhang Nanjing University of Chinese Medicine Tao Liu ( [email protected] ) Nanjing University of Chinese Medicine https://orcid.org/0000-0002-7654-2995 Research Article Keywords: HSV-2 infection,Microarray analysis,Histospecic gene expression Posted Date: May 12th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-517057/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract Background: Herpes simplex virus type 2 infects the body and becomes an incurable and recurring disease. The pathogenesis of HSV-2 infection is not completely clear. Methods: We analyze the GSE18527 dataset in the GEO database in this paper to obtain distinctively displayed genes(DDGs)in the total sequential RNA of the biopsies of normal and lesioned skin groups, healed skin and lesioned skin groups of genital herpes patients, respectively.The related data of 3 cases of normal skin group, 4 cases of lesioned group and 6 cases of healed group were analyzed.The histospecic gene analysis , functional enrichment and protein interaction network analysis of the differential genes were also performed, and the critical components were selected. Results: 40 up-regulated genes and 43 down-regulated genes were isolated by differential performance assay. Histospecic gene analysis of DDGs suggested that the most abundant system for gene expression was the skin, immune system and the nervous system.Through the construction of core gene combinations, protein interaction network analysis and selection of histospecic distribution genes, 17 associated genes were selected CXCL10,MX1,ISG15,IFIT1,IFIT3,IFIT2,OASL,ISG20,RSAD2,GBP1,IFI44L,DDX58,USP18,CXCL11,GBP5,GBP4 and CXCL9.The above genes are mainly located in the skin, immune system, nervous system and reproductive system.
  • Reduced Concentrations of the B Cell Cytokine Interleukin 38 Are Associated with Cardiovascular Disease Risk in Overweight Subjects

    Reduced Concentrations of the B Cell Cytokine Interleukin 38 Are Associated with Cardiovascular Disease Risk in Overweight Subjects

    Eur. J. Immunol. 2020. 00: 1–10 DOI: 10.1002/eji.201948390 Dennis M. de Graaf et al. 1 Clinical Allergy and inflammation Research Article Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects DennisM.deGraaf1,2 , Martin Jaeger2 ,IngeC.L.vanden Munckhof2 , Rob ter Horst2 ,KikiSchraa2 , Jelle Zwaag3 , Matthijs Kox3 , Mayumi Fujita4 , Takeshi Yamauchi4, Laura Mercurio5 , Stefania Madonna5 , Joost H.W. Rutten2 , Jacqueline de Graaf2 ,NielsP.Riksen2 , Frank L. van de Veerdonk2 , Mihai G. Netea2 , Leo A.B. Joosten2 and Charles A. Dinarello1,2 1 Department of Medicine, University of Colorado Denver, Aurora, CO, USA 2 Department of Internal Medicine and Radboud Institute of Molecular Life Science (RIMLS), Radboud University Medical Center, Nijmegen, The Netherlands 3 Department of Intensive Care Medicine and Radboud Institute of Molecular Life Science (RIMLS), Radboud University Medical Center, Nijmegen, The Netherlands 4 Department of Dermatology, University of Colorado Denver, Aurora, CO, USA 5 Laboratory of Experimental Immunology, IDI-IRCCSFondazione Luigi M. Monti, Rome, Italy The IL-1 family member IL-38 (IL1F10) suppresses inflammatory and autoimmune con- ditions. Here, we report that plasma concentrations of IL-38 in 288 healthy Europeans correlate positively with circulating memory B cells and plasmablasts. IL-38 correlated negatively with age (p = 0.02) and was stable in 48 subjects for 1 year. In comparison with primary keratinocytes, IL1F10 expression in CD19+ B cells from PBMC was lower, whereas cell-associated IL-38 expression was comparable. In vitro, IL-38 is released from CD19+ B cells after stimulation with rituximab.
  • Structural Basis for Cytosolic Double-Stranded RNA Surveillance by Human Oligoadenylate Synthetase 1

    Structural Basis for Cytosolic Double-Stranded RNA Surveillance by Human Oligoadenylate Synthetase 1

    Structural basis for cytosolic double-stranded RNA surveillance by human oligoadenylate synthetase 1 Jesse Donovan, Matthew Dufner, and Alexei Korennykh1 Department of Molecular Biology, Princeton University, Princeton, NJ 08540 Edited by Jennifer A. Doudna, University of California, Berkeley, CA, and approved December 19, 2012 (received for review October 23, 2012) The human sensor of double-stranded RNA (dsRNA) oligoadenylate Results and Discussion synthetase 1 (hOAS1) polymerizes ATP into 2′,5′-linked iso-RNA (2- Overview of the hOAS1•dsRNA•dATP Ternary Complex. To un- 5A) involved in innate immunity, cell cycle, and differentiation. We derstand how OAS1 recognizes dsRNA, we conducted cocrys- report the crystal structure of hOAS1 in complex with dsRNA and tallization screening with hOAS1 and dsRNA sequences derived 2′-deoxy ATP at 2.7 Å resolution, which reveals the mechanism of from RNA constructs known to activate the sensor (2). Single cytoplasmic dsRNA recognition and activation of oligoadenylate cocrystals were obtained only with dsRNA having 18 bp and a ser- synthetases. Human OAS1 recognizes dsRNA using a previously endipitously constructed sequence GGCUUUUGACCUUUAU- uncharacterized protein/RNA interface that forms via a conforma- GC. The structure of the ternary complex was determined at 2.7 Å tional change induced by binding of dsRNA. The protein/RNA in- resolution (Table S1). In the cocrystal structure, hOAS1 is bound to fi terface involves two minor grooves and has no sequence-speci c one face of the RNA double-helix (Fig. 1A and Figs. S1 and S2)and contacts, with the exception of a single hydrogen bond between the dsRNA termini are unobstructed by the protein (Table S2).
  • Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis

    Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis

    UC Davis UC Davis Previously Published Works Title Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. Permalink https://escholarship.org/uc/item/34d4m5nk Journal Frontiers in immunology, 5(MAR) ISSN 1664-3224 Authors Selmi, Carlo Cavaciocchi, Francesca Lleo, Ana et al. Publication Date 2014 DOI 10.3389/fimmu.2014.00128 Peer reviewed eScholarship.org Powered by the California Digital Library University of California ORIGINAL RESEARCH ARTICLE published: 28 March 2014 doi: 10.3389/fimmu.2014.00128 Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis Carlo Selmi 1,2*, Francesca Cavaciocchi 1,3, Ana Lleo4, Cristina Cheroni 5, Raffaele De Francesco5, Simone A. Lombardi 1, Maria De Santis 1,3, Francesca Meda1, Maria Gabriella Raimondo1, Chiara Crotti 1, Marco Folci 1, Luca Zammataro1, Marlyn J. Mayo6, Nancy Bach7, Shinji Shimoda8, Stuart C. Gordon9, Monica Miozzo10,11, Pietro Invernizzi 4, Mauro Podda1, Rossana Scavelli 5, Michelle R. Martin12, Michael F. Seldin13,14, Janine M. LaSalle 12 and M. Eric Gershwin2 1 Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Milan, Italy 2 Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis, Davis, CA, USA 3 BIOMETRA Department, University of Milan, Milan, Italy 4 Liver Unit and Center for Autoimmune Liver Diseases, Humanitas Clinical and Research Center, Milan, Italy 5 National Institute of Molecular Genetics (INGM), Milan, Italy 6 University of Texas Southwestern, Dallas, TX, USA 7 Mt. Sinai University, NewYork, NY, USA 8 Clinical Research Center, National Nagasaki Medical Center, Nagasaki, Japan 9 Henry Ford Hospital, Detroit, MI, USA 10 Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy 11 Division of Pathology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy 12 Genome Center and M.I.N.D.
  • Table SII. Significantly Differentially Expressed Mrnas of GSE23558 Data Series with the Criteria of Adjusted P&lt;0.05 And

    Table SII. Significantly Differentially Expressed Mrnas of GSE23558 Data Series with the Criteria of Adjusted P<0.05 And

    Table SII. Significantly differentially expressed mRNAs of GSE23558 data series with the criteria of adjusted P<0.05 and logFC>1.5. Probe ID Adjusted P-value logFC Gene symbol Gene title A_23_P157793 1.52x10-5 6.91 CA9 carbonic anhydrase 9 A_23_P161698 1.14x10-4 5.86 MMP3 matrix metallopeptidase 3 A_23_P25150 1.49x10-9 5.67 HOXC9 homeobox C9 A_23_P13094 3.26x10-4 5.56 MMP10 matrix metallopeptidase 10 A_23_P48570 2.36x10-5 5.48 DHRS2 dehydrogenase A_23_P125278 3.03x10-3 5.40 CXCL11 C-X-C motif chemokine ligand 11 A_23_P321501 1.63x10-5 5.38 DHRS2 dehydrogenase A_23_P431388 2.27x10-6 5.33 SPOCD1 SPOC domain containing 1 A_24_P20607 5.13x10-4 5.32 CXCL11 C-X-C motif chemokine ligand 11 A_24_P11061 3.70x10-3 5.30 CSAG1 chondrosarcoma associated gene 1 A_23_P87700 1.03x10-4 5.25 MFAP5 microfibrillar associated protein 5 A_23_P150979 1.81x10-2 5.25 MUCL1 mucin like 1 A_23_P1691 2.71x10-8 5.12 MMP1 matrix metallopeptidase 1 A_23_P350005 2.53x10-4 5.12 TRIML2 tripartite motif family like 2 A_24_P303091 1.23x10-3 4.99 CXCL10 C-X-C motif chemokine ligand 10 A_24_P923612 1.60x10-5 4.95 PTHLH parathyroid hormone like hormone A_23_P7313 6.03x10-5 4.94 SPP1 secreted phosphoprotein 1 A_23_P122924 2.45x10-8 4.93 INHBA inhibin A subunit A_32_P155460 6.56x10-3 4.91 PICSAR P38 inhibited cutaneous squamous cell carcinoma associated lincRNA A_24_P686965 8.75x10-7 4.82 SH2D5 SH2 domain containing 5 A_23_P105475 7.74x10-3 4.70 SLCO1B3 solute carrier organic anion transporter family member 1B3 A_24_P85099 4.82x10-5 4.67 HMGA2 high mobility group AT-hook 2 A_24_P101651
  • The Evolution of the Viral RNA Sensor OAS1 in Old World Monkeys and Cetartiodactyls

    The Evolution of the Viral RNA Sensor OAS1 in Old World Monkeys and Cetartiodactyls

    City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 2-2016 The Evolution of the Viral RNA Sensor OAS1 in Old World Monkeys and Cetartiodactyls Ian Fish Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/759 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] The Evolution of the Viral RNA Sensor OAS1 in Old World Monkeys and Cetartiodactyls by Ian Fish The City University of New York 2016 i Copyright 2016 by Fish, Ian All rights reserved ii This manuscript has been read and accepted for the Graduate Faculty in Biology in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. ______________ ______________________________ Date Chair of Examining Committee Dr. Stéphane Boissinot ______________ ______________________________ Date Executive Officer Dr. Laurel Eckhardt Supervising Committee Members: ____________________________ Dr. Cathy Savage-Dunn, Queens College ____________________________ Dr. Susan Rotenberg, Queens College ____________________________ Dr. Shaneen Singh, Brooklyn College ____________________________ Dr. Margaret MacDonald, The Rockefeller University iii Abstract The Evolution of the Viral RNA Sensor OAS1 in Old World Monkeys and Cetartiodactyls author: Ian Fish advisor: Dr. Stéphane Boissinot Animals produce an array of sensors patrolling the intracellular environment poised to detect and respond to viral infection. The oligoadenylate synthetase family of enzymes comprises a crucial part of this innate immune response, directly signaling endonuclease activity responsible for inhibiting viral replication.